During extended treatment, bleeding risk was similar for apixaban and rivaroxaban.
Your search for apixaban returned 51 results
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
Less knowledge about OTC products with potentially serious interactions linked to increased use